

University of Chicago Medicine adopts CT:VQ™

30 January 2026

Highlights

- University of Chicago Medicine, ranked among the top U.S. hospitals for Pulmonology and Lung Surgery, expands agreement with 4DMedical to include commercial CT:VQ™ deployment
- UChicago becomes the fifth U.S. academic medical centre to adopt CT:VQ™, following Stanford, Cleveland Clinic, UC San Diego Health and University of Miami
- Expanded arrangement includes renewed imaging analysis platform agreement and commercial contract incorporating an initial package of prepaid CT:VQ™ scans
- Five leading academic medical centre deployments achieved within five months of FDA clearance, validating 4DMedical's commercialisation strategy and further solidifying its position with key opinion leaders and influential reference sites
- Professor Kyle Hogarth, Interventional Pulmonologist at UChicago Medicine, highlights the clinical advantages CT:VQ™ provides in complex lung disease assessment and procedural planning

Melbourne, Australia, 30 January 2026 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces that it has expanded its partnership with University of Chicago Medicine (UChicago Medicine) to include commercial deployment of CT:VQ™.

CT:VQ™ commercial launch at UChicago Medicine

UChicago Medicine is consistently ranked among the United States' premier centres for complex lung disease. Its Interventional Pulmonology and Advanced Diagnostics programs have been early adopters of functional imaging, using 4DMedical analyses to enhance understanding of regional ventilation and to support clinical decisions in COPD, small airways disease, and pre-procedural planning.

Building on the long-standing partnership, where UChicago Medicine utilises 4DMedical's comprehensive portfolio of structural and functional lung imaging products including CT LVAS™, the expanded agreement now incorporates a commercial contract for CT:VQ™ with an initial pre-paid scan package to accelerate clinical deployment. While this initial scan package is not financially material, UChicago Medicine is an opinion leading site with significant potential to scale CT:VQ™ utilisation as clinical workflows are established and procedural demand grows.

Professor Kyle Hogarth, Director of Bronchoscopy, has spoken across multiple recent investor webinars about the clinical advantages CT:VQ™ provides in his practice, particularly its value in evaluating regional ventilation and perfusion for intervention planning and ongoing patient management, derived from CT scans he was already ordering as part of the care pathway.

4DMedical MD/CEO and Founder Andreas Fouras said:

University of Chicago Medicine is one of the nation's most respected AMCs and a pioneer in medical innovation. Their expansion of our partnership to include CT:VQ™ represents powerful validation of both the clinical value our technology delivers and the strength of our commercialisation approach.

UChicago Medicine has been a fantastic partner in showing how functional and structural lung imaging can really make a difference in clinical practice. Professor Kyle Hogarth has been an outstanding advocate for

For personal use only
The future of lung health

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



advanced respiratory imaging, and we're thrilled to see UChicago expand their use of our technology portfolio with CT:VQ™.

In under five months since FDA clearance, we've now established CT:VQ™ at five of America's leading academic medical centers: Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, and University of Chicago Medicine. This rapid adoption by elite institutions demonstrates both the transformative potential of CT:VQ™ and the strength of our go-to-market execution.

The excitement that CT:VQ™ is creating in lung health is now clearly tangible for all to see. These prestigious AMCs serve as powerful anchors for our commercialisation strategy. Combined with our Philips partnership and growing commercial pipeline, we are building unstoppable momentum as we establish CT:VQ™ as the new standard of care in pulmonary imaging.

The momentum continues to build, and I look forward to sharing further progress with shareholders as we advance through 2026.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com